Most people diagnosed with pleural mesothelioma, the most common form, live about 12 to 14 months after diagnosis. But that number varies widely depending on where the cancer is located, what cell type it is, how far it has spread, and the person’s overall health. Some people live five years or longer, while others have only months. Understanding what drives those differences can help you make sense of a prognosis.
Survival Rates by Stage
How far mesothelioma has spread at the time of diagnosis is the single biggest factor in life expectancy. The American Cancer Society tracks five-year relative survival rates for pleural mesothelioma (the type that forms in the lining of the lungs) based on data from 2015 to 2021:
- Localized (cancer is confined to the lining where it started): 23% five-year survival
- Regional (cancer has spread to nearby tissues or lymph nodes): 15% five-year survival
- Distant (cancer has spread to other parts of the body): 11% five-year survival
Across all stages combined, the five-year relative survival rate is 15%. That means about 15 out of every 100 people diagnosed with pleural mesothelioma are alive five years later. These numbers reflect averages across thousands of patients. Individual outcomes can fall well above or below them.
Where the Cancer Forms Matters
Mesothelioma can develop in several locations, and the site makes a dramatic difference in prognosis. Pleural mesothelioma, which accounts for the majority of cases, carries the survival rates described above. Peritoneal mesothelioma, which forms in the lining of the abdomen, has significantly better outcomes.
National averages for peritoneal mesothelioma show a one-year survival rate of 92%, a three-year rate of 74%, a five-year rate of 65%, and a ten-year rate of 39%. That gap is partly because peritoneal mesothelioma responds better to certain treatments, including heated chemotherapy delivered directly into the abdomen during surgery. If you or someone you know has been diagnosed, the specific type matters enormously when interpreting survival statistics.
Cell Type and Its Effect on Prognosis
Under a microscope, mesothelioma cells fall into three categories, and each one behaves differently.
Epithelioid cells make up roughly 70% of all pleural mesothelioma cases and carry the best prognosis, with a median survival of about 14 months. These cells tend to grow more slowly and respond better to treatment.
Sarcomatoid cells account for about 20% of cases and are the most aggressive. They resist treatment more stubbornly and are associated with the shortest survival times. Biphasic mesothelioma contains a mix of both cell types. In one study of 118 biphasic patients, median survival was 11.2 months. In biphasic cases, the proportion of sarcomatoid cells influences the outlook: a higher percentage of sarcomatoid cells generally means a worse prognosis.
Stage 4 Without Treatment
For people with advanced mesothelioma who choose not to pursue aggressive treatment, or for whom treatment isn’t an option, life expectancy is shorter. Stage 4 pleural mesothelioma patients receiving only supportive or palliative care typically survive 6 to 8 months. For stage 4 peritoneal mesothelioma without treatment, survival is often closer to 6 months.
Palliative care at this stage focuses on managing pain, difficulty breathing, and fluid buildup. It won’t extend life in the way chemotherapy or immunotherapy might, but it can meaningfully improve the quality of the time that remains.
Does Surgery Help?
This is a question many patients and families ask, and the answer is less straightforward than it once seemed. For years, aggressive surgical procedures were considered a cornerstone of mesothelioma treatment. But recent clinical trial data has challenged that assumption.
The MARS 2 trial, a major randomized study published in The Lancet Respiratory Medicine, compared surgery plus chemotherapy against chemotherapy alone for pleural mesothelioma. Patients who received surgery actually had shorter median survival (19.3 months) than those who received chemotherapy alone (24.8 months). All randomized trials published to date have found a higher risk of death with major cytoreductive surgery compared to standard care alone.
This doesn’t mean surgery is never appropriate, but it does mean the decision is nuanced. Treatment plans today increasingly rely on immunotherapy and chemotherapy combinations, sometimes with more limited surgical procedures to manage symptoms rather than attempt a cure.
Factors That Shift the Outlook
Beyond stage, location, and cell type, several other factors influence how long someone lives with mesothelioma:
- Age and overall health: Younger patients and those with fewer other health conditions tend to tolerate treatment better and live longer. Most mesothelioma patients are diagnosed in their 60s or 70s, decades after asbestos exposure.
- Gender: Women with mesothelioma generally have better survival outcomes than men, though the reasons aren’t entirely clear.
- Response to treatment: Some tumors shrink significantly with chemotherapy or immunotherapy. When they do, survival improves substantially. How well the cancer responds in the first few months of treatment is one of the strongest predictors of long-term outcome.
It’s also worth noting that the survival statistics most commonly cited are based on people diagnosed years ago. Treatments have improved, particularly with the introduction of immunotherapy combinations that became standard in 2020 and beyond. Current patients may do better than the numbers from older datasets suggest.
Long-Term Survivors
While mesothelioma is an aggressive cancer, some people do live well beyond the averages. About 15% of pleural mesothelioma patients reach the five-year mark, and for peritoneal mesothelioma, that number is 65%. Long-term survivors tend to share certain characteristics: earlier-stage disease at diagnosis, epithelioid cell type, younger age, and strong response to initial treatment.
No two cases are identical. Survival statistics describe populations, not individuals. They’re useful for understanding the general landscape, but they can’t predict what will happen to any one person. Some patients outlive their prognosis by years.